William Irvin, MD
Hematology & Oncology · Midlothian, VANPI 1700903242
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Medtronic at 37.7% of the total. 2025 is the largest year on record at $96, 7.4 times the $13 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in VA, where the typical reported total is $1,232.
Across 5 payments — averaging $35.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$66
- Merz North America, Inc.$41
- Takeda Pharmaceuticals U.S.A., Inc.$32
- Iovance Biotherapeutics, Inc.$24
- GSK$13
Across 431 payments — averaging $9922.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.5M
- Pfizer$986K
- AstraZeneca$503K
- Eli Lilly$220K
- Biontech SE$214K
- Regeneron$205K
- plus $660K from 8 others
What the payments were for
- Food & beverage$176100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $66 |
| Merz North America, Inc. | 1 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Iovance Biotherapeutics, Inc. | 1 | $24 |
| GSK | 1 | $13 |
How this compares
$176 in reported general payments places this provider in the 15th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 14 | $229,608 |
| EliquisApixaban | 12 | $9,444 |
| Anastrozole | 391 | $7,739 |
| Exemestane | 34 | $7,676 |
| Letrozole | 90 | $2,441 |
| Ondansetron Hcl | 42 | $1,824 |
| Tamoxifen Citrate | 55 | $1,511 |
| Duloxetine Hcl | 53 | $902 |
| Prochlorperazine Maleate | 38 | $797 |
| Dexamethasone | 31 | $580 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 30 | $371 |
| Alendronate Sodium | 27 | $204 |
| Amitriptyline Hcl | 12 | $157 |
| Olanzapine | 21 | $154 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Midlothian
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.